

Docket Number: 037003-0280646

PATENT APPLICATION

Client Reference: 1992-30-0029CP1C3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of

ANDERSON et al.

Group Art Unit: 1644

Application No.: 09/911,692

Examiner: Unassigned

Filed: July 25, 2001

Confirmation No.: 8484

For: THERAPEUTIC APPLICATION OF CHIMERIC AND RADIOLABELED
 ANTIBODIES TO HUMAN B LYMPHOCYTE RESTRICTED DIFFERENTIATION
 ANTIGEN FOR TREATMENT OF B CELL LYMPHOMA

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
 P. O. Box 1450
 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is being filed before the mailing date of the first Office Action on the merits in the present application. No certification or fee is required.

Respectfully submitted,

Thomas A. Cawley, Jr., Ph.D.
 Registration Number 40,944

Date: November 21, 2003
 PILLSBURY WINTHROP LLP
 Telephone: (703) 905-2000
 Facsimile: (703) 905-2500
 P.O. Box 10500
 McLean, VA 22102
 TAC/JBM:ntb

□□

FORM PTO-1449 (modified)
 To: U.S. Department of Commerce
 (PW FORM PAT-1449)
 Patent and Trademark Office



Atty. Dkt. No.	M#	Client Ref.
	0280646	1992-30-0029CP1C3

Applicant: ANDERSON et al.

Appln. No.: 09/911,692

Filing Date: July 17, 2001

Examiner: Unassigned Group Art Unit: 1644

Date: November 21, 2003 Page 1 of 1

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date
AR	6,183,744 B1	02/2001	GOLDENBERG			
BR	6,306,393 B1	10/2001	GOLDENBERG			
CR						
DR						
ER						
FR						

FOREIGN PATENT DOCUMENTS

	Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract	Translation Readily Available
GR						
HR						
IR						
JR						
KR						
LR						

OTHER

MR	Kaminski, et al., "Radioimmunotherapy of Advanced B-Cell Lymphoma with Non Bone Marrow Ablative Doses of 131-I MB-1 Antibody," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 3, No. 1, Abstract No. 83.
NR	Kaminski, et al., "Radioimmunodetection (RID) and Non Marrow Ablative Radioimmunotherapy (RIT) of B-Cell Lymphoma With 131-I MB-1 Antibody," 1990, <i>Proceedings of ASCO</i> , Vol. 9, Abstract No. 1051.
OR	Wahl, et al., "Radioimmunotherapy of B-Cell Lymphoma with I131 MB-1 Monoclonal Antibody," <i>The Journal of Nuclear Medicine: Proceedings of the 37th Annual Meeting</i> , p. 852, Abstract No. 622.
PR	Kaminski, et al., "Phase I Trial Results of 131-I MB-1 Antibody Radioimmunotherapy (RAIT) of B-Cell Lymphoma," 1990, <i>Antibody Immunoconjugates, and Radiopharmaceuticals</i> , Vol. 4, No. 1, p. 36, Abstract No. 66.
QR	Kaminski, et al., "Phase I Evaluation of 131-I MB-1 Antibody Radioimmunotherapy (RIT) of B-Cell Lymphoma," 1990, <i>Blood</i> , Vol. 76, No. 10, p. 355a, Abstract No. 1409.
RR	Kaminski, et al., "Imaging, Dosimetry, and Radioimmunotherapy With Iodine 131-Labeled Anti-CD37 Antibody in B-Cell Lymphoma," 1992, <i>Journal of Clinical Oncology</i> , Vol. 10, No. 11, pp.1696-1711.
SR	
TR	
UR	
VR	

Examiner	Date Considered:
----------	------------------

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.